Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGynecological OncologyradiotherapyDiseaseCervical CancerSubgroupICD10C53.-MeSHUterine Cervical NeoplasmsSequenceKEYNOTE-826: PEMB200/PACL175/CISP50, Cervical Ca, C1-6 (PID1900) -|- PEMB200, C7+ (PID1893)KEYNOTE-826: PEMB200/PACL175/CISP50/BEVA15, Cervical Ca, C1-6 (PID1891) -|- PEMB200/BEVA15, C7+ (PID2251) or PEMB200, C7+ (PID1893).KEYNOTE-826: PEMB200/PACL175/CRBP5, Cervical Ca, C1-6 (PID1892) -|- PEMB200, C7+ (PID1893)KEYNOTE-826: PEMB200/PACL175/CRBP5/BEVA15, Cervical Ca, C1-6 (PID1890) -|- PEMB200/BEVA15, C7+ (PID2251) or PEMB200, C7+ (PID1893).PACL135/CISP30/Radiation, Cervical Ca (PID1990)ChemotherapyChemo-substanceBevacizumabCarboplatinCemiplimabCisplatinPaclitaxelPembrolizumabTisotumab vedotinTopotecanChemo-substanceBevacizumabCarboplatinCemiplimabCisplatinPaclitaxelPembrolizumabTisotumab vedotinTopotecanChemo-substanceBevacizumabCarboplatinCemiplimabCisplatinPaclitaxelPembrolizumabTisotumab vedotinTopotecanChemo-substanceBevacizumabCarboplatinCemiplimabCisplatinPaclitaxelPembrolizumabTisotumab vedotinTopotecanNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%NaphazolinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%NaphazolinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%NaphazolinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%NaphazolinePegfilgrastimPotassium chlorideNo. Substances13456789Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseTherapy intentioncurativepalliativeRisksAbdominal PainAdrenal InsufficiencyAllergic ReactionAlopeciaAnemia Hb below 8g/dlAnorexiaArthalgiaAstheniaBleedingCardiotoxicityConjunctivitisConstipationDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaFistulasGastrointestinal ToxicityHand-Foot SyndromeHemorrhageHepatotoxicityHyperglycemiaHypertensionHyperthyroidismHypokalemiaHypophysitisHypothyroidismIncrease AminotransferasesInfectionsLeukopeniaMyalgiasNeuropathyNeutropeniaOral MucositisPainPneumonitisPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic EventVisual DisturbancesVomiting only studiesPublicationAuthorChung HCColombo NHong DSHuang HKatanyoo KKitagawa RLong HSehouli JTewari KSDiseasefortgeschrittenes oder rezidiviertes Zervixkarzinom, Stadium IVb, ECOG 0-2fortgeschrittenes Zervix-Ca, nach Vorbehandlung, ECOG 0-1fortgeschrittenes Zervixkarzinom, Stadium IIb-IVaLokal fortgeschrittenes oder metastasierten Zervixkarzinom, ohne Möglichkeit einer kurativen Therapie, Erstlinie, ECOG 0-1Metastasierendes, wiederkehrendes oder persistierendes Zervix Ca, ECOG/GOG 0-1metastasiertes, wiederkehrendes oder persistierendes Zervix Ca, ECOG/GOG 0-1metastasiertes oder wiederkehrendes Zervixkarzinom, Platin-Vortherapie, keine Taxan-Vortherapie, ECOG 0-2Zervix-Ca, metastasiert oder rezidiviert, Progress nach platinhaltiger Therapie, ECOG 0-1Zervix-Ca lokal fortgeschritten, nicht operabel oder metastasiert, nach platinhaltiger Therapie, ECOG 0-1Zervix Ca, FIGO IB1, IB2, IIA1, IIA2, nach Hysterektomie und pelviner LymphadenektomieZervixkarzinom, FIGO Stadium IB2-IIB oder IBI + Risikofaktoren, nach radikaler HysterektomieOriginCollaborative Innovation Center for Cancer Medicine, Guangzhou, China, STARS trialDepartment of Radiology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, ThailandMayo Clinic College of Medicine, Rochester, MN, GOG StudyNOGGO-AGONRG Oncology-Gynecologic Oncology Group (GOG240)NTT Medical Center Tokyo, Trial JCOG0505The University of Texas MD Anderson Cancer Center, Texas, USA, innovaTV 201 studyUniversity of California, Irvine, CA, EMPOWER- Cervical 1/GOG-3016/ENGOT-cx9University of Milan-Bicocca, European Institute of Oncology IRCCS, Italy, KEYNOTE-826 trialYonsei Cancer Center, Yonsei University College of Medicine, Seoul, KEYNOTE 158Protocols in Revision 17 protocols foundProtocols under revision.Carboplatin 2 / Radiation, Cervical Cancer (PID1939)Cemiplimab 350, Cervical Cancer (PID1981)Cisplatin 40 / Radiation, Cervical Cancer Adjuvant (PID540)Paclitaxel 135 / Cisplatin 30 / Radiation, Cervical Carcinoma (PID1990)Paclitaxel 175 / Carboplatin 5 followed by Radiation, Cervical Cancer adjuvant (PID97)Paclitaxel 175 / Carboplatin 5, Cervical Cancer (PID1937)Paclitaxel 175 / Cisplatin 50 / Bevacizumab 15, Cervical Cancer (PID600)Paclitaxel 175 / Topotecan 0.75 / Bevacizumab 15, Cervical Cancer (PID769)Pembrolizumab 200 / Bevacizumab 15, Cervical Cancer, Cycle 7+ (PID2251)Pembrolizumab 200 / Paclitaxel 175 / Carboplatin 5 / Bevacizumab 15, Cervical Cancer, Cycle 1-6 (PID1890)Pembrolizumab 200 / Paclitaxel 175 / Carboplatin 5, Cervical Cancer, Cycle 1-6 (PID1892)Pembrolizumab 200 / Paclitaxel 175 / Cisplatin 50 / Bevacizumab 15, Cervical Cancer, Cycle 1-6 (PID1891)Pembrolizumab 200 / Paclitaxel 175 / Cisplatin 50, Cervical Cancer, cycle 1-6 (PID1900)Pembrolizumab 200, Cervical Cancer (PID1331)Pembrolizumab 200, Cervical Cancer, Cycle 7+ (PID1893)Tisotumab Vedotin 2, Cervical Carcinoma (PID2002)Topotecan 0.75 / Cisplatin 50, Cervical Cancer (PID1938)